



## Neogap appoints leading international cell therapy expert to its Board

Neogap Therapeutics AB, a Swedish clinical-stage biotechnology company developing personalised immunotherapy for cancer treatment, announces the appointment of Professor Jonas Mattsson as a new member of the Board of Directors. He brings leading clinical expertise in cell therapy at a stage when the company is advancing its first clinical programme and strengthening its structure for continued clinical and strategic development.



Professor Jonas Mattsson is a globally recognised authority in cell therapy, with more than 300 publications and extensive experience from both academic research and clinical practice.

Jonas Mattsson is currently Director of the Hans Messner Allogeneic Transplant Program at Princess Margaret Cancer Centre in Toronto and Professor of Medicine at the University of Toronto. He also holds the Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation, established as the world's first professorship in cell therapy. Previously, he was Professor at Karolinska Institutet and Senior Consultant at Karolinska University Hospital and Oslo University Hospital.

“Neogap is developing a personalised cell therapy that addresses one of the greatest challenges in modern oncology – the ability to selectively target the unique mutations of a tumour. By using a patient’s own T cells and training them to recognise the tumour-specific targets, the therapy creates a targeted treatment with the potential to cure patients who currently have no remaining treatment options. This is particularly relevant in colorectal cancer, a major disease with rising incidence, especially among younger patients. I look forward to contributing to the company’s continued development,” says Jonas Mattsson.

“Jonas brings clinical expertise and an international perspective with deep roots in advanced cell therapy. His experience will be of great value as we progress in our clinical development programme and strengthen the company for the next stages,” says Samuel Svensson, CEO of Neogap Therapeutics.



*Project reference number: 190185439 – NEOpTTL. Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EISMEA. Neither the European Union nor the granting authority can be held responsible for them.*

**For more information, please contact:**

Samuel Svensson, CEO

Email: [samuel.svensson@neogap.se](mailto:samuel.svensson@neogap.se)

Phone: +46 733 54 21 94

**About Neogap Therapeutics**

Neogap Therapeutics is a Swedish clinical-stage biotechnology company focused on developing personalised cancer immunotherapy using the patient's own cells. The therapy is based on the company's two technologies PIOR<sup>®</sup> and EpiTCer<sup>®</sup>. PIOR<sup>®</sup> is sophisticated software that uses DNA sequencing data from the patient and machine learning algorithms to select tumour-specific mutations. Then, EpiTCer<sup>®</sup> is used to multiply T cells that can recognize and attack the selected tumor-specific targets. Neogap is located at Cancer Center Karolinska in Stockholm. To learn more about Neogap and its cutting-edge research, please visit [neogap.se](http://neogap.se) and follow Neogap on [LinkedIn](#).